About Biogen Inc.
Focused on neuroscience drugs for Alzheimer's, multiple sclerosis, and spinal muscular atrophy. Revenue hinges on Leqembi adoption and legacy MS franchise erosion. No dividend. Binary event risk around clinical data makes vol spike periodically — put sellers get paid well but face pipeline uncertainty.
Biotechnology